Cancer Discovery

Scientists build a new model of CAR-T cells — Ones with Powerful “Armor” that allow them to fight Solid Tumors

Engineered T-cell therapy, and in particular CAR T-cells, have shown efficacy in CD-19+ blood cancer such as lymphomas and leukemias. However, to date, T-cell therapies have found little success in solid tumors – in part due to the immunosuppressive tumor microenvironment. Checkpoint inhibitors, on the other hand, have been proven effective at empowering the immune system to fight a variety of solid tumors. The checkpoint inhibitor antibody binds to a
Biotechnology Cell Therapy Clinical Trials rare diseases Vaccines

FDA Announces First Approval of Targeted Therapy Based on Basket Study

Precision medicine clinical trial leads to approval of first treatment for Erdheim-Chester disease The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever drug approved for ECD, a rare blood disorder. This landmark approval came as